학술논문

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Document Type
article
Source
New England Journal of Medicine. 374(4)
Subject
Rare Diseases
Cancer
Genetics
Clinical Research
Lymphoma
Hematology
6.1 Pharmaceuticals
6.2 Cellular and gene therapies
Evaluation of treatments and therapeutic interventions
Administration
Oral
Agammaglobulinaemia Tyrosine Kinase
Aged
Antineoplastic Agents
Benzamides
Chromosome Deletion
Diarrhea
Disease-Free Survival
Dose-Response Relationship
Drug
Female
Headache
Humans
Leukemia
Lymphocytic
Chronic
B-Cell
Male
Middle Aged
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Pyrazines
Recurrence
Medical and Health Sciences
General & Internal Medicine
Language
Abstract
BackgroundIrreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index. Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors.MethodsIn this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib. Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion.ResultsThe median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated immunoglobulin heavy-chain variable genes. No dose-limiting toxic effects occurred during the dose-escalation portion of the study. The most common adverse events observed were headache (in 43% of the patients), diarrhea (in 39%), and increased weight (in 26%). Most adverse events were of grade 1 or 2. At a median follow-up of 14.3 months, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease. Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%. No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred.ConclusionsIn this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion. (Funded by the Acerta Pharma and others; ClinicalTrials.gov number, NCT02029443.).